Introduction
============

P450 oxidoreductase (POR) deficiency (ORD) is a variant of congenital adrenal hyperplasia that is not caused by mutations in a steroidogenic enzyme itself, but in the co-factor enzyme POR [@bib1]. POR facilitates electron transfer from NADPH to key enzymes involved in glucocorticoid and sex steroid synthesis, 17α-hydroxylase/17,20 lyase (CYP17A1), CYP21A2 (21-hydroxylase) and CYP19A1 (aromatase). Therefore, mutant POR results in clinical presentation with disordered sex development (DSD) and glucocorticoid deficiency [@bib1]. Intriguingly, individuals of both sexes may present with DSD, i.e. 46,XX DSD and 46,XY DSD. While undervirilization of affected male individuals is readily explained by insufficient sex steroid synthesis, virilization in girls is thought to be consequent to the exaggerated activity of an alternative pathway towards androgen synthesis that is active in fetal life and ceases activity shortly after birth [@bib1]. Individuals affected by ORD also often present with skeletal malformations, most likely consequent to impaired synthesis of cholesterol [@bib4] and retinoic acid metabolism [@bib6], both of which play a crucial role in the regulation of fetal bone development and growth [@bib5].

In addition to facilitating steroid and sterol synthesis, POR provides electrons to all major drug-metabolizing cytochrome P450 (CYP) enzymes, and thus it is conceivable that mutant POR will also disrupt drug and xenobiotic metabolism ([Fig. 1](#fig1){ref-type="fig"}). Five CYP enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) are responsible for the metabolism of more than 80% of all drugs [@bib8]. CYP3A4 represents the major player involved in the metabolism of more than half of existing drugs, notably also in the inactivation of steroid hormones including glucocorticoids and sex steroids [@bib9].

A functional impact of sequence variants in the *POR* gene on hepatic drug metabolism by *POR* sequence has been suggested by a number of *in vitro* studies [@bib10] and a recent *in vivo* study in healthy individuals [@bib14]. However, the significance of mutant POR for human drug metabolism has not been studied yet in the clinical context of ORD. Here, we have studied the activities of the five major drug-metabolizing CYP enzymes in two individuals carrying the *POR* variant A287P, the most frequently observed disease-causing *POR* mutation in Caucasians.

Subjects and methods
====================

Subjects
--------

A 48-year-old patient with congenital adrenal hyperplasia due to ORD and her clinically unaffected 72-year-old mother participated in the study. The neonatal and pubertal presentation of this patient has been reported elsewhere (J Idkowiak, unpublished observations); in brief, she presented at birth with severely virilized external genitalia, i.e. 46,XX DSD, and was wrongly assigned to the male gender. At the age of 5 years, sex reassignment was prompted by the birth of a virilized sister. Owing to lack of spontaneous pubertal development, puberty had been induced at the age of 17 years by equine oestrogens and progesterone. Detailed assessment at the age of 24 years revealed elevated serum progesterone and 17OH-progesterone, low serum androgens, partial adrenal insufficiency with an impaired cortisol response to ACTH stimulation and clinical and radiological evidence of mild dysmorphic features (low set ears, clinodactyly, camptodactyly and brachydactyly). Blood pressure was elevated on repeated measurements (systolic 140--160 mmHg and diastolic 90--95 mmHg).

Oestrogen/progestin replacement was continued until the age of 37 years, when she was diagnosed with breast cancer, despite a negative family history. The tumour was 3 cm in diameter, with a mixed histological picture featuring foci of ductal adenocarcinoma as well as stromal myxoid changes; tumour tissue was negative for oestrogen and progesterone receptor staining and Her-2/neu amplification. Oestrogen/progestin replacement was stopped post surgical follow-up until her current age of 49 years did not reveal a recurrence.

Methods
-------

### POR and CYP enzyme genotyping

To ascertain the diagnosis of ORD, genetic analyses were performed after obtaining written informed consent and with approval of the South Birmingham Research Ethics Committee. The coding region of the *POR* gene (GeneID 5447) was amplified as previously described [@bib1], employing genomic DNA from the patient and her mother.

In addition to *POR* sequencing, we performed genotyping for common variant alleles of the genes encoding the major drug-metabolizing CYP enzymes since such sequence variants have been shown to contribute to an individual\'s drug response. Analyses included the determination of variant alleles \*2 and \*3 of CYP2C9 [@bib15], allele \*2 of CYP2C19 [@bib16] and alleles \*3, \*4, \*5, \*6 and the gene duplication of CYP2D6 [@bib17]. \**n* denotes the individual allele as decided by the Human CYP Allele Nomenclature Committee (<http://www.cypalleles.ki.se/>).

### *In vivo* low dose cocktail phenotyping

Both subjects underwent *in vivo* phenotyping to assess the activities of the major hepatic drug-metabolizing CYP enzymes carried out after obtaining informed consent and with approval of the ethics committee of the University Hospital Cologne. Low doses of validated substrates selective for each of the five major drug-metabolizing CYP enzymes were orally administered simultaneously as a 'cocktail' ([Table 1](#tbl1){ref-type="table"}), thereby allowing for estimation of several metabolic pathways in a single assessment [@bib18]. Phenotyping was performed under in-patient conditions. After an overnight fast, blood samples were drawn before and 1, 3, 6 and 24 h after the oral administration of 150 mg caffeine, 125 mg tolbutamide, 20 mg omeprazole, 30 mg dextromethorphan hydrobromide and 2 mg midazolam at 0900 h ([Table 1](#tbl1){ref-type="table"}). Plasma concentrations of the probe drugs and their metabolites were determined by liquid chromatography/tandem mass spectrometry as previously described [@bib19]. The results of the cocktail phenotyping were projected on to the reference range obtained in normal controls (CYP1A2: *n*=768 [@bib20]; CYP2C9: *n*=26 [@bib21]; CYP2C19: *n*=153, estimated according to [@bib22]; CYP2D6: *n*=51, unpublished in-house data; CYP3A4: *n*=66 [@bib23]).

Results
=======

ORD was confirmed by *POR* sequencing, which revealed subjects 1 and 2 as homozygous and heterozygous carriers respectively of the c.852G→C (g.29,556G→C) mutation in exon 8 of the *POR* gene, encoding for an amino acid change from alanine to proline in position 287 of the POR protein, p.A287P.

Both subjects had *CYP2C19* genotypes indicative of a rapid metabolizer phenotype, i.e. high enzymatic activity, and their *CYP2C9* genotypes were predictive of normal activity ([Table 2](#tbl2){ref-type="table"}). *CYP2D6* genotyping found *CYP2D6* gene duplication in subject 1 (patient), consistent with an ultrarapid metabolizer phenotype, while variant alleles identified in subject 2 (mother) predicted a rapid metabolizer phenotype ([Table 2](#tbl2){ref-type="table"}).

However, despite *CYP* genotyping results predictive of normal to high enzymatic activities, *in vivo* drug cocktail phenotyping revealed low activities of all tested CYP enzymes in both subjects ([Fig. 2](#fig2){ref-type="fig"}). The patient and her mother had similarly decreased activities of CYP1A2 (oral caffeine clearance (ml/min per kg body weight); subject 1, 0.25; subject 2, 0.35) and CYP2C9 (plasma tolbutamide concentration 24 h post dose (μg/ml); subject 1, 13.9; subject 2, 7.8), clearly below the 5th percentile of a normal reference population ([Fig. 2](#fig2){ref-type="fig"}). Also CYP2C19 activity was similarly low in both subjects (plasma omeprazole/5-hydroxyomeprazole 4 h post dose; subject 1, 2.79; subject 2, 2.66), albeit still within the lowest quartile of the normal reference range ([Fig. 2](#fig2){ref-type="fig"}). However, with regards to CYP2D6 and CYP3A4, we observed lower metabolic capacities for subject 1 who was homozygous for POR A287P than for subject 2 who carried only one mutant POR A287P allele. Subject 1 showed clearly subnormal conversion of the probe drugs, whereas observed metabolic capacities of CYP2D6 and CYP3A4 for subject 2 still varied within the lowest normal range (CYP2D6: plasma dextromethorphan/dextrorphan 3 h post dose; subject 1, 5.05; subject 2, 0.68; CYP3A4: oral midazolam clearance (L/hl); subject 1, 10.7; subject 2, 39.7) ([Fig. 2](#fig2){ref-type="fig"}).

Discussion
==========

Here, we have provided *in vivo* evidence for impaired drug metabolism as a consequence of mutant POR. *In vivo* cocktail phenotyping revealed grossly diminished activities of drug-metabolizing CYP enzymes in the two subjects carrying the *POR* A287P mutation, a disease-causing *POR* variant most frequently found in Caucasians [@bib1]. However, it is remarkable that even heterozygosity for this allele was sufficient to clearly decrease metabolic capacities of all five major drug-metabolizing CYP enzymes, as demonstrated in the patient\'s mother. Of note, the clinically observed drug-metabolizing CYP enzyme activities in the two subjects were severely decreased despite *CYP* genotyping results predictive of normal to high activities. This suggests that the effect of genetic variation in *POR* on interindividual variability in drug metabolism may be at least as important as that of variant *CYP* alleles.

We have previously shown that POR A287P differentially affects the activity of electron-accepting steroidogenic CYP enzymes, namely a preferential inhibition of 17-hydroxylase over 21-hydroxylase, as demonstrated *in vitro* and also *in vivo* by increased urinary excretion of corticosterone over cortisol metabolites, causing a relative accumulation of steroids with mineralocorticoid-like activity [@bib24]. The clinical significance of this finding is clearly reflected by the clinical phenotype of the current patient who presented with manifest arterial hypertension at the age of 24 years, most likely a consequence of mild mineralocorticoid excess. In addition, it has been shown that POR A287P does not result in any inhibition of CYP19A1 activity [@bib25], further highlighting the differential effects of this mutant. Thus, it is entirely possible that distinct *POR* variants may have only modest effects on steroidogenic CYP enzymes but could severely disrupt drug-metabolizing CYP enzymes.

*POR* is a highly polymorphic gene with more than 140 documented sequence variants in the POR-coding region, including 40 present on more than 1% of alleles [@bib26]. A number of *in vitro* studies and a recent *in vivo* study have attempted to address the correlation between genetic variation in *POR* and drug-metabolizing CYP enzyme activities [@bib10]. A recent study demonstrated reduced *in vitro* CYP3A4 activity due to POR A287P [@bib13]. However, another study demonstrated complete abolishment of CYP1A2 and CYP2C19 activities by POR A287P *in vitro* [@bib10], which contrasts with our *in vivo* finding of clearly diminished albeit still detectable CYP1A2 and CYP2C19 activities in our patient carrying homozygous A287P. This emphasizes that *in vitro* assays are valuable, but will not always correctly reflect complex systems such as the CYP--POR drug-metabolizing complex, where genetic variants within more than one gene may impact on the enzymatic activities observed *in vivo*. Obviously, we cannot exclude that the observed reduction in drug-metabolizing enzyme activities in our two subjects of similar familial genetic background could be due to another, hitherto not yet identified genetic variation. However, the significance of POR for drug metabolism was also indicated by previous rodent-based studies analysing liver-specific *Por* deletion, demonstrating disruption of cholesterol and bile acid metabolism [@bib28] and reduced activation of the chemotherapeutic pro-drug cyclophosphamide [@bib29]. Another possible caveat is that the heterozygous mother was 78 years of age, and the drug metabolism profile was compared with CYP genotype-matched controls but could not be directly compared with age-matched controls as such data are not available. However, there is no general loss of hepatic CYP activity with age, as previously shown *in vitro* [@bib30] and *in vivo* [@bib31], which would explain the uniform low activity in the mother.

Of note, our patient developed breast cancer at the very early age of 37 years, despite a negative family history. It is tempting to speculate about the possible contribution of mutant POR to the development of this early onset breast cancer. CYP3A4 is the major enzyme involved in the inactivation of steroid hormones including glucocorticoids and sex steroids [@bib9], and we found that *in vivo* CYP3A4 activity was grossly reduced in our patient, who had received standard dose oestrogen replacement for 20 years prior to being diagnosed with breast cancer. Impairment of CYP3A4 activity, as documented in our patient, will have undoubtedly resulted in delayed breakdown of and increased exposure to oestrogen, a well-known risk factor for breast cancer. CYP3A4 activity is known to display broad interindividual variability and, in contrast to other drug-metabolizing CYP enzymes, convincing associations between variant *CYP3A4* alleles and observed *in vivo* enzymatic activity are lacking [@bib32]. Thus, variant *POR* might be a more important modulator of CYP3A4 function than genetic variation in *CYP3A4* itself.

Our finding of grossly impaired drug-metabolizing activities in our patient despite carrying variant *CYP* alleles predictive of high enzymatic activities inevitably poses the question whether this should alter clinical management. We feel that based on our results, low dose cocktail phenotyping, a low risk diagnostic procedure, should be considered in all patients with CAH caused by ORD to determine whether future drug therapy and, importantly, also steroid replacement therapy including glucocorticoid and sex steroids require individually tailored dosing.
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![P450 oxidoreductase (POR) transfers electrons to all microsomal cytochrome P450 (CYP) enzymes. POR thereby impacts on the function of three major metabolic systems involving microsomal CYP enzymes: steroid synthesis in adrenal glands and gonads, cholesterol synthesis (e.g. in developing bone) and metabolism of steroids, drugs and other xenobiotics, mainly in the liver; drug-metabolizing microsomal CYP enzymes: CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4; steroidogenic microsomal CYP enzymes: CYP17A1 (17α-hydroxylase/17,20 lyase), CYP21A2 (21-hydroxylase) and CYP19A1 (aromatase); microsomal CYP enzymes involved in sterol synthesis and metabolism: CYP51A1 (14α-lanosterol demethylase) and SQLE (squalene epoxidase); microsomal CYP enzymes involved in retinoic acid metabolism: CYP26A1, CYP26B1 and CYP26C1.](EJE100764f01){#fig1}

![*In vivo* low dose cocktail phenotyping for assessment of drug-metabolizing CYP enzyme activities in P450 oxidoreductase deficiency. The results of the cocktail phenotyping in subject 1 (patient, A287P/A287P) and subject 2 (mother, A287P/WT) projected on to the reference range obtained in normal controls, with the boxes representing the 25th to 75th percentile and the whiskers indicating 5th and 95th percentiles respectively. Results are represented as multiples of the median enzyme activity observed in the respective normal reference cohorts (for details, see the Methods section).](EJE100764f02){#fig2}

###### 

*In vivo* low dose drug cocktail phenotyping for assessment of drug-metabolizing cytochrome P450 (CYP) enzymes including selective substrates employed, respective doses and phenotyping parameters.

  ----------------------------------- ------------------------------- --------------- ---------------------------------------------------------------------------------------------------
  **Drug-metabolizing CYP enzymes**   **Drug**                        **Dose** (mg)   **Phenotyping parameter** (unit)
  CYP1A2                              Caffeine                        150             Oral caffeine clearance (ml/min per kg body weight)
  CYP2C9                              Tolbutamide                     125             Plasma concentration of tolbutamide 24 h post dose (μg/ml)
  CYP2C19                             Omeprazole                      20              Ratio of the molar plasma concentrations of omeprazole over 5-hydroxyomeprazole 3 h post dose (−)
  CYP2D6                              Dextromethorphan hydrobromide   30              Ratio of the molar plasma concentrations of dextromethorphan over dextrorphan 3 h post dose (−)
  CYP3A4                              Midazolam                       2               Oral midazolam clearance (L/hl)
  ----------------------------------- ------------------------------- --------------- ---------------------------------------------------------------------------------------------------

###### 

Results of cytochrome P450 (*CYP*) genotyping in the patient with P450 oxidoreductase (POR) deficiency (ORD) due to homozygous POR A287P (subject 1) and her clinically unaffected, heterozygous mother (subject 2), listing the identified variant alleles (\*) of *CYP2C9*, *CYP2C19* and *CYP2D6* previously described to affect enzymatic activity.

  ----------------------------------- --------------------------------------------------------------------------------------- ----------------------
                                      **Predicted drug metabolizer phenotype** (according to variant *CYP* allele genotype)   
  **Drug-metabolizing CYP enzymes**   Subject 1 (A287P/A287P)                                                                 Subject 2 (A287P/WT)
  CYP2C9                              Intermediate (\*1/\*2)                                                                  Rapid (\*1/\*1)
  CYP2C19                             Rapid (\*1/\*1)                                                                         Rapid (\*1/\*1)
  CYP2D6                              Ultrarapid (2×\*2/\*1)                                                                  Rapid (\*1/\*1)
  ----------------------------------- --------------------------------------------------------------------------------------- ----------------------
